Global /China /Healthcare /Biotechnology /688426

Jiangsu CoWin Biotech Co., Ltd.

688426

• SSE: 688426 • Delayed

20.84CNY 2.2%

3.08 USD

As of 24 June 2026, Jiangsu CoWin Biotech Co., Ltd. has a market cap of $330.58M USD, ranking #17965 globally and #5524 in China. It ranks #1627 in the Healthcare sector, and #310 in the Biotechnology industry.

Global Rank

17965

Country Rank

5524

Sector Rank

1627

Industry Rank

310

Key Stats

Market Cap

$330.58MUSD

2.24B CNY

Enterprise Value

$248.59MUSD

1.68B CNY

Revenue (TTM)

$28.53MUSD

193.52M CNY

EBITDA (TTM)

-$13.28MUSD

-89.9M CNY

Net Income (TTM)

-$15.83MUSD

-107.41M CNY

EBITDA Margin

-46%

Profit Margin

-56%

PS Ratio

11.6

PB Ratio

1.7

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Biotechnology

CEO

Chun Xiang Wang open_in_new

Employees

770

Founded

2010

Website

cwbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
2.2%	2%	0.9%	-26%	-27%	-14%	17%	-38%	-48%

News

Markets

Exchange	Ticker	Price	Quotes
Shanghai Stock Exchange (SSE / SHA) MIC: XSHG PRIMARY	688426 江苏康为世纪生物科技股份有限公司 Class A ISIN: CNE100005NM2 Shares Out.: Shares Outstanding: 34.313M¹ Shares Float: 34.306M² TV: TradingView: SSE: 688426 SA: Stock Analysis: SHA: 688426 YF: Yahoo Finance: 688426.SS GF: Google Finance: SHA: 688426 BA: Barron's: 688426 MS: Morningstar: XSHG: 688426	20.84 CNY	TV: TradingView: SSE: 688426 SA: Stock Analysis: SHA: 688426 YF: Yahoo Finance: 688426.SS GF: Google Finance: SHA: 688426 BA: Barron's: 688426 MS: Morningstar: XSHG: 688426

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Jiangsu CoWin Biotech Co., Ltd.

Jiangsu CoWin Biotech Co., Ltd. engages in the research and development, production, and sale of biological products in China. The company provides molecular diagnostic raw material enzymes, nucleic acid collection and protection agents, nucleic acid extraction and purification kits, molecular diagnostic testing reagents, etc. It also offers medical device products, nucleic acid collection and protection, PCR, RT-PCR, and qPCR products, molecular diagnosis, isothermal amplification, nucleic acid mass spectrometry, next generation sequencing, nucleic acid extraction and purification, marker clone transfection, antibody, protein detection products, and scientific research instruments. The company was founded in 2010 and is headquartered in Taizhou, China.

Similar Companies

Industry: Biotechnology (China)

Name	Market Cap (USD) diff.	PE	Country
WuXi Biologics (Cayman) Inc. SHEK: 2269	$17.44B 136.71B HKD 5K%	25.3	China
CSPC Pharmaceutical Group Ltd. SHEK: 1093	$12.19B 95.58B HKD 4K%	22.1	China
Sichuan Kelun Pharmaceutical Co., Ltd. SHE: 002422	$7.99B 54.23B CNY 2K%	34.4	China
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. SSE: 603392	$7.32B 49.69B CNY 2K%	-	China
3SBio Inc. SHEK: 1530	$7.08B 55.5B HKD 2K%	5.8	China
Hangzhou Tigermed Consulting Co., Ltd. SHE: 300347	$6.71B 45.52B CNY 2K%	61.6	China

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 55K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 48K%	19.0	United States
argenx SE EBR: ARGX	$47.29B 41.39B EUR 14K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.45B 68.19T KRW 13K%	35.5	South Korea
Lonza Group AG SIX: LONN	$41.67B 33.71B CHF 13K%	37.2	Switzerland
CSL Ltd. ASX: CSL	$41.65B 60.27B AUD 12K%	29.3	Australia

chevron_leftBack